Skip to main content
. Author manuscript; available in PMC: 2015 May 1.
Published in final edited form as: Clin Cancer Res. 2014 Feb 28;20(9):2338–2349. doi: 10.1158/1078-0432.CCR-13-3157

Figure 3. Gene expression profiling and gene set enrichment assay (GSEA) in EBV+ diffuse large B-cell lymphoma (DLBCL).

Figure 3

A. A unique gene expression signature was found in EBV+ DLBCL compared with EBV-negative DLBCL. B. DLBCLs with co-expression of EBER and CD30 showed a gene expression signature distinct from cases with EBER+ CD30−. C and D. GSEA validated enhanced activity of NF-κB pathway and JAK/STAT pathway in EBV+ DLBCL.